Shares of major US health insurers slid after hours as Washington proposed keeping Medicare Advantage base payments effectively flat for 2027 and moved to strip out a key source of risk-adjustment revenue. The draft from the Centers for Medicare and Medicaid Services calls for a 0.09% increase, versus Wall Street expectations for 4% to 6%. Humana fell as much as 13% in late trading, while UnitedHealth, CVS, Elevance, Cigna and Centene also sank.
The proposal lands at the core of the managed care investment case. Private plans have relied on steady, mid-single-digit annual rate increases to fuel growth while funding richer benefits and absorbing higher medical costs. A near-zero update resets that math. Investors were braced for a tighter stance after last year’s utilization uptick, but not this tight: expectations clustered around 4% to 6% to cover trend, coding and star rating shifts. Instead, CMS opened with a near freeze and layered on policy that makes the net impact worse. The sector selloff reflects more than headline fear. It’s a fundamental repricing of cash flow trajectories, especially for carriers with heavy Medicare Advantage exposure. Humana’s concentration left it most exposed; UnitedHealth’s diversification through Optum offers some cushion, but not immunity. CVS and Elevance face dual hits via Aetna and Anthem-branded plans, respectively.
Beyond the nominal rate, CMS moved to eliminate payments tied to diagnoses sourced from insurer medical chart reviews that are not linked to a specific medical visit. The agency estimates that step alone would reduce the 2027 payment rate by 1.53 percentage points. That change targets a long-running controversy over “upcoding,” where plans have been accused by watchdogs of using chart reviews and health risk assessments to bolster risk scores and payments without corresponding clinical encounters. If finalized as proposed, the shift would lower risk scores, diminish plan revenue per member, and compress margins—particularly for carriers that leaned hard on chart review programs. The message from policymakers is explicit: payment accuracy over revenue optimization. Regulators have tightened risk adjustment rules and ramped audits in recent years; this proposal goes further by cutting off a revenue lever that has been central to the business model.
With rate relief off the table, plans will have to move quickly on 2027 bids. The levers are familiar but painful: raise premiums, cut supplemental benefits, tighten networks, reduce broker commissions, or chase medical cost savings that may be slow to materialize. Medical loss ratios will push higher absent an offset. Several carriers were already grappling with elevated outpatient utilization and pharmacy inflation; layering a revenue headwind on top threatens earnings estimates. The knock-on effect for consumers could be fewer extras—dental, vision, and fitness perks—and narrower provider access as plans reprice product designs. Cutting benefits risks star ratings and member churn, but eating the cost pressures risks profit deterioration. Investors are recalibrating for a lower margin glide path in Medicare Advantage, and for slower earnings growth trajectories tied to this book of business.
The proposal arrives with a clear political signal. The administration is prioritizing taxpayer savings and program integrity in Medicare Advantage, a program now covering more than half of eligible seniors. A harder line on rates and coding fits that narrative. Street expectations for a sizable positive “final rule bump” now look optimistic. There is a comment period ahead, and historically CMS has adjusted components—normalization factors, trend assumptions, star rating changes—in response to industry pushback. The final announcement is due in April, with plan bids following in June. Carriers, trade groups and provider partners will argue that the combination of flat rates and coding curbs will force benefit cuts for seniors. Whether CMS offers a phase-in of the chart review elimination or tweaks the risk score normalization will determine whether the net impact remains deeply negative or merely tight. Analysts have already warned the process looks more politically influenced, and that stock recovery could take time even if the final numbers soften.
Exposure matters. Humana is the most Medicare Advantage-centric of the majors, with earnings power disproportionately tied to that line. That concentration explains the double-digit after-hours drop. UnitedHealth’s scale and Optum’s provider, pharmacy and services franchises offer diversification, but Medicare Advantage remains a key profit center and a driver of growth; a flat rate and coding headwinds hit both UNH’s plan and provider economics. CVS’s Aetna unit and Elevance’s Anthem-brand MA portfolios are sizable enough to dent consolidated guidance if the rule lands close to draft form. Cigna, with relatively less Medicare Advantage exposure, may be more insulated on the margin, though broad managed care sentiment tends to move as a pack on rate headlines. Centene, focused more on Medicaid, still felt the downdraft as investors reassessed managed care policy risk across government programs.
The immediate equity reaction—down as much as 13% for sector leaders in after-hours trading—signals a valuation reset. Managed care multiples had been supported by the premium growth and steady returns of Medicare Advantage. A credible path to high-single-digit earnings growth looks tougher if rates stall and risk adjustment tightens. Options markets reflect the shock: implied volatility spiked as traders rushed to hedge, and liquidity thinned in the extended session. This is less about quarter-to-quarter noise and more about the terminal value of the MA franchise. If carriers can pass through cost and preserve benefits, earnings durability returns. If not, the market will price in structurally lower returns on capital for the MA book. Buy-the-dip instincts may give way to a wait-for-final-rule posture, especially with management teams likely to reset 2027 planning assumptions on upcoming calls.
Several technical elements will decide how punitive the final outcome is. The risk score normalization factor can swing revenue by hundreds of basis points depending on assumed coding trends. The treatment of star ratings and quality bonus payments matters, particularly for carriers clustered around critical thresholds. Phase-in mechanics for the chart review change—if any—could blunt the near-term hit. Trend assumptions for medical costs and pharmacy, including GLP-1 utilization, will influence plan bid calculus even if CMS does not explicitly set them. Watch for whether CMS acknowledges the interaction effects between rate, risk adjustment and quality bonuses that compound at the county benchmark level. Industry comment letters will center on these mechanics and present data on benefit disruption if the proposal is finalized intact.
Management commentary now becomes the next catalyst. Carriers will reassess 2026 guidance sensitivity to 2027 prep costs and comment on bid strategy. Expect talk of tightening broker commissions and stricter distribution oversight, which can affect membership growth. Providers will push for higher contracted rates as plans pare benefits, creating tension in networks. Pharmacy cost management, already a focal point, will intensify. The question for investors is whether carriers can craft 2027 bids that defend margins without triggering dangerous enrollment losses. The June bid deadline leaves a short window to rework product designs, and the extent of benefit pullbacks will be a tell on confidence. If CMS softens the final, expect stocks to retrace some losses; if not, plan for a multi-year reset in MA profitability assumptions.
Medicare Advantage has been the engine of managed care growth for a decade, driven by demographics, aggressive benefits, and favorable policy. The draft rule challenges that equilibrium. A 0.09% base update and the removal of chart review-derived diagnoses would force a harder trade-off between benefits and margins, with political cover shifting toward cost control. The market reaction is not just fear; it is a repricing of a growth narrative that now carries greater policy risk. The sector will live and die by the April final rule, 2027 bids, and evidence that carriers can pass through cost without losing members. Until then, volatility is the baseline and the burden of proof sits with the plans.
